Skin cancer goes by several names depending on which type of skin cell turns malignant. The three most common types are basal cell carcinoma, squamous cell carcinoma, and melanoma. Beyond those, a handful of rarer cancers can also start in the skin, each with its own name and behavior. A recent survey found that while about 82% of patients recognized “melanoma” as a skin cancer, only around 70% identified basal cell carcinoma and roughly 59% identified squamous cell carcinoma as skin cancers, which suggests the terminology trips people up more than you might expect.1JAMA Dermatology. Patient Comprehension of Skin Cancer–Related Terminology
The Two Most Common Skin Cancers
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) together form a group often called “non-melanoma skin cancers” or “keratinocyte carcinomas.” Both arise from keratinocytes, the cells that make up the outer layer of your skin, but they originate in different layers and behave differently.2PubMed Central. Pathophysiology, Histopathology, and Differential Diagnostics of Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
Basal cell carcinoma is the single most common cancer in humans, full stop. It develops in the basal cells at the bottom of the epidermis and grows slowly. It almost never spreads to distant parts of the body, but it can cause serious local damage if left untreated, eating into surrounding tissue over months or years. BCCs come in several subtypes that look quite different under a microscope and on the skin surface. Nodular BCC, the most familiar variety, tends to appear as a pearly or waxy bump with visible blood vessels. Superficial BCC looks more like a flat, reddish patch and is easy to mistake for eczema. Morpheaform (also called sclerosing) BCC can resemble a scar and is harder to spot because its borders blend into normal skin. Infiltrative BCC has poorly defined edges and tends to extend deeper.3PubMed Central. Dermoscopic features of basal cell carcinoma and its subtypes: A systematic review
Squamous cell carcinoma is the second most common skin cancer. It develops in the squamous cells of the upper epidermis and carries more risk than BCC because it can spread to lymph nodes and distant organs, especially if it grows large or develops in certain high-risk locations like the lip or ear. SCC often starts as a firm, red nodule or a flat sore with a scaly crust. Chronic ultraviolet radiation exposure is the primary driver, and actinic keratoses, those rough, sandpaper-like patches that appear on sun-damaged skin, are the main precursor lesion.4PubMed Central. Exposome and Skin. Part 2. The Influential Role of the Exposome, Beyond UVR, in Actinic Keratosis, Bowen’s Disease and Squamous Cell Carcinoma
Precancers and In-Situ Forms You Might See on a Report
If you have ever had a dermatologist freeze or scrape a spot on your skin, the pathology report might reference terms that sound like cancer but technically refer to something earlier in the process. Actinic keratosis (AK) is the most common example. Doctors sometimes call these “precancers” because they represent the first visible sign of chronic sun damage in the skin’s squamous cells. Most AKs never become invasive cancer, but they sit on a spectrum that can lead to SCC.
Bowen’s disease is another term you might encounter. It refers to squamous cell carcinoma “in situ,” meaning the abnormal cells are still confined to the outermost skin layer and have not invaded deeper tissue. Bowen’s disease progresses to invasive SCC in roughly 3% to 5% of cases, and about a third of those invasive tumors can spread.5PubMed Central. Development of poorly differentiated invasive squamous cell carcinoma in giant Bowen’s disease The boundaries between actinic keratosis, Bowen’s disease, and invasive SCC are not always clear-cut, even under a microscope; pathologists sometimes use additional markers to tell them apart.6PubMed. P27 and mib1 expression in actinic keratosis, Bowen disease, and squamous cell carcinoma
The same survey that tested patient understanding found that only about 14% of patients knew what “actinic” means and only about 22% understood “dysplastic nevus,” a term used for an atypical mole.1JAMA Dermatology. Patient Comprehension of Skin Cancer–Related Terminology If any of these terms appear on your pathology report and your doctor does not explain them, it is worth asking. The words sound intimidating, but many of them describe conditions that are highly treatable when caught early.
Melanoma and Its Subtypes
Melanoma develops in the melanocytes, the cells responsible for producing the pigment that gives skin its color. It is far less common than BCC or SCC but far more dangerous because of its tendency to spread to other organs. The medical name is simply “melanoma” or “malignant melanoma,” and it is divided into four major subtypes based on how the tumor looks and grows.7PubMed Central. Skin Cancer: Epidemiology, Screening and Clinical Features of Acral Lentiginous Melanoma (ALM), Melanoma In Situ (MIS), Nodular Melanoma (NM) and Superficial Spreading Melanoma (SSM)
- Superficial spreading melanoma (SSM): The most common subtype. It tends to grow outward across the skin surface before invading deeper layers, which often gives you a window to catch it early. It usually appears as a flat or slightly raised discolored patch with irregular borders.
- Nodular melanoma (NM): Grows vertically into the skin from the start rather than spreading outward first, making it more aggressive. It often looks like a raised, dome-shaped bump that may be dark brown, black, or even skin-colored.
- Lentigo maligna melanoma (LMM): Develops on chronically sun-damaged skin, most often on the face and neck of older adults. It starts as a flat, slowly enlarging patch called lentigo maligna (the in-situ phase) and can take years to become invasive.
- Acral lentiginous melanoma (ALM): Occurs on the palms, soles, and under the nails, areas that do not get much sun exposure. It is the rarest subtype overall but is the most common form of melanoma in people with darker skin tones.8PubMed Central. Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease
These subtypes are not just academic labels. Nodular melanoma and acral lentiginous melanoma carry worse outcomes than superficial spreading and lentigo maligna melanoma. In one study, five-year overall survival rates ranged from about 84% for lentigo maligna melanoma down to roughly 46% for nodular melanoma. Relapse rates for non-metastatic cases were also substantially higher in NM (about 40%) and ALM (about 35%) compared with SSM (about 24%) and LMM (about 10%).9The American Journal of Dermatopathology. Major Histotypes in Skin Melanoma: Nodular and Acral Lentiginous Melanomas Are Poor Prognostic Factors for Relapse and Survival
You might also see “melanoma in situ” on a pathology report, which means the melanoma cells are still confined to the very top layer of skin and have not yet invaded deeper. This is the earliest and most curable stage. Another variant worth knowing is amelanotic melanoma, which lacks the typical dark pigment and can appear pink, red, or skin-colored, making it easy to miss.10PubMed Central. Unusual location of subungual amelanotic melanoma in 39-year-old patient
Rare Skin Cancers With Less Familiar Names
Beyond the big three, several uncommon cancers can originate in or on the skin. They are worth knowing about because they are easy to overlook, and some of them are aggressive.
Merkel cell carcinoma (MCC) is a rare cancer with neuroendocrine features, meaning it arises from Merkel cells, which are involved in the sensation of touch. MCC typically appears as a painless, firm, red or violet nodule, often on the head or neck. Risk factors include sun exposure, advanced age, immunosuppression, and infection with a virus called Merkel cell polyomavirus.11PubMed Central. Merkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease Despite being rare, MCC has a higher mortality rate than melanoma stage-for-stage, so early detection matters enormously.
Kaposi sarcoma (KS) is a cancer that develops from the cells lining blood and lymph vessels. It appears as purplish, reddish, or brown patches or nodules on the skin and is driven by a virus called Kaposi’s sarcoma herpesvirus (also known as human herpesvirus-8). It is most commonly seen in people with weakened immune systems, including those with HIV/AIDS or organ transplant recipients.12PubMed Central. Kaposi’s sarcoma herpesvirus/Human herpesvirus-8 (KSHV/HHV8), and the oncogenesis of Kaposi’s sarcoma
Dermatofibrosarcoma protuberans (DFSP) is an extremely rare soft-tissue sarcoma that begins in the deeper layers of the skin. It grows slowly and rarely spreads to distant organs, but it has a high tendency to come back locally after surgery if not removed with wide margins.13PubMed Central. Dermatofibrosarcoma: a rare neoplasm of skin
Cutaneous lymphomas are cancers of the immune system that show up first in the skin. The most common type is mycosis fungoides, a cutaneous T-cell lymphoma that accounts for roughly 53% of all cutaneous lymphomas. It can look like ordinary patches of dry or red skin in its early stages, which is one reason it is sometimes mistaken for eczema or psoriasis for years before diagnosis. Sézary syndrome is a related but more aggressive leukemic variant, characterized by widespread redness, enlarged lymph nodes, and malignant cells circulating in the blood.14PubMed Central. Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management 15PubMed. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis
The Keratoacanthoma Question
One name that generates genuine disagreement among dermatologists is keratoacanthoma (KA). Keratoacanthomas are dome-shaped growths with a central crater filled with keratin. They can pop up quickly, sometimes reaching full size within weeks. Some pathologists consider KA a well-differentiated variant of squamous cell carcinoma, while others view it as a distinct entity that is essentially benign because many KAs will shrink and disappear on their own if left alone.16PubMed Central. Keratoacanthoma versus Squamous-Cell Carcinoma: Histopathological Features and Molecular Markers
In practice, most clinicians treat KA as if it were SCC, because distinguishing the two under the microscope can be difficult and the consequences of undertreatment are serious.17PubMed Central. Distinguishing Keratoacanthoma from Well-Differentiated Cutaneous Squamous Cell Carcinoma Using Single-Cell Spatial Pathology If your biopsy report mentions keratoacanthoma, your doctor will almost certainly recommend removal, regardless of which side of the debate they fall on.
Staging Terms You Might Encounter
When skin cancer is diagnosed, it is assigned a stage using the TNM system, which stands for tumor, nodes, and metastasis. These letters describe the size and depth of the primary tumor (T), whether nearby lymph nodes are involved (N), and whether the cancer has spread to distant sites (M). The most recent edition of the staging manual made several changes relevant to skin cancer.18PubMed. Novel Additions to the AJCC’s New Staging Systems for Skin Cancer
For non-melanoma skin cancers like SCC, staging now relies on the measured diameter of the tumor along with risk factors such as nerve invasion. For melanoma, two measurements dominate the pathology report. Breslow thickness measures the depth of the tumor in millimeters, now recorded to the nearest tenth of a millimeter. Clark level describes how deeply the melanoma has invaded through the layers of skin. Both are independent predictors of outcome.19PubMed. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging The current staging system also looks at whether the melanoma surface is ulcerated, meaning whether the top layer of skin over the tumor has broken down, which is a sign of more aggressive disease.20British Journal of Dermatology. The new 8th edition of TNM staging and its implications for skin cancer
If these terms appear on your pathology report, the key numbers to pay attention to are the Breslow thickness (thinner is better), the T stage (lower is better), and whether ulceration or sentinel lymph node involvement is mentioned. Your doctor will translate the staging into a treatment plan, but knowing which terms carry the most weight helps you ask better questions.
How Genomics Is Adding New Names
Traditionally, melanoma subtypes were defined by what they look like under a microscope. That system is still used every day, but molecular research has added another layer of classification based on the genetic mutations driving the cancer. Melanomas are now also grouped into four genomic subtypes: BRAF-mutant, NRAS-mutant, NF1-loss, and triple wild-type (tumors without any of those three driver mutations).21PubMed Central. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities
This matters to patients because it directly affects treatment. If your melanoma carries a BRAF mutation, you may be eligible for targeted therapies that specifically block the protein that mutation produces. If your tumor is NRAS-mutant or triple wild-type, the treatment approach shifts toward immunotherapy or clinical trials testing other strategies. In other words, the “name” of your melanoma is no longer just about anatomy and appearance. It is also about which gene is misbehaving, and that can change which drugs your oncologist recommends.
This genomic layer has not replaced the traditional subtype names. Instead, it supplements them. A pathology report for advanced melanoma might describe the tumor as a superficial spreading melanoma that is BRAF V600E-mutant, combining the old morphological label with the new molecular one. The two naming systems capture different information: the histological name tells clinicians how the tumor grows, while the genomic name tells them what is fueling it.
When a Skin Growth Is Not Cancer at All
Not every growth on the skin is malignant, and the terminology can blur the line in confusing ways. Seborrheic keratoses, for example, are extremely common benign growths that can look alarming. They are waxy, stuck-on-appearing growths that range from tan to dark brown and sometimes get mistaken for melanoma. They are not cancerous, though they can occasionally be found alongside or overlapping with a melanocytic nevus (mole), including atypical moles.22PubMed Central. Dysplastic nevus associated with seborrheic keratosis
A dysplastic nevus is an atypical mole that has some features under the microscope suggesting it sits between a normal mole and early melanoma. Having dysplastic nevi does not mean you have cancer, but it does mean you carry a higher risk and should get regular skin checks. Actinic keratosis is precancerous, seborrheic keratosis is benign, and dysplastic nevus is a risk marker. Three “keratosis” and “nevus” terms, three entirely different levels of concern. If there is one practical takeaway from all these names, it is that the words on a pathology report are not interchangeable and the distinctions between them are worth understanding.